Amikacin Liposomal/Neb.Accessr
Brand name: Arikayce
Rank #254 of 500 drugs by total cost
$50.5M
Total Cost
3,394
Total Claims
$50.5M
Total Cost
178
Prescribers
$15K
Cost per Claim
130
Beneficiaries
3,533
30-Day Fills
$284K
Avg Cost/Provider
19
Avg Claims/Provider
About Amikacin Liposomal/Neb.Accessr
Amikacin Liposomal/Neb.Accessr (sold as Arikayce) was prescribed 3,394 times by 178 Medicare Part D providers in 2023, costing the program $50.5M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 251 | Sodium,calcium,mag,pot Oxybate (Xywav) | $51.1M | 3,234 |
| 252 | Eslicarbazepine Acetate (Aptiom) | $51.1M | 31,472 |
| 253 | Risdiplam (Evrysdi) | $51.1M | 1,891 |
| 254 | Amikacin Liposomal/Neb.Accessr (Arikayce) | $50.5M | 3,394 |
| 255 | Diclofenac Epolamine (Licart) | $50.5M | 72,299 |
| 256 | Donepezil Hcl (Donepezil Hcl) | $50.3M | 3,178,215 |
| 257 | Paliperidone (Paliperidone Er) | $49.3M | 129,516 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology